about
Role of pertuzumab in the treatment of HER2-positive breast cancerRetinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsMolecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerRole of RUNX2 in Breast CarcinogenesisA requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 miceUsing large-scale molecular data sets to improve breast cancer treatment.The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling.Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenograftsStandard of care and promising new agents for triple negative metastatic breast cancerRB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.Identification of anti-ErbB2 dual variable domain immunoglobulin (DVD-Ig™) proteins with unique activities.HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.Medicinal chemistry for 2020HGUE-C-1 is an atypical and novel colon carcinoma cell line.Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.Triple-negative breast cancer: are we making headway at least?The Therapeutic Challenge of Targeting HER2 in Endometrial CancerThe molecular profile of luminal B breast cancerSynthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop.p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2.Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers.Validation of a radiosensitivity molecular signature in breast cancer.Dual HER2-targeted approaches in HER2-positive breast cancer.Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX.CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models.HER2 Overexpression in Retinoblastoma: A Potential Therapeutic Target?Self-assembly of peptide amphiphiles for drug delivery: the role of peptide primary and secondary structures.Trastuzumab emtansine: determining its role in management of HER2+ breast cancer.Pertuzumab, trastuzumab and docetaxel reduced the recurrence of brain metastasis from breast cancer: a case report.Intranasal delivery of stem cell-based therapies for the treatment of brain malignancies.Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer.Oncodriver inhibition and CD4+ Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies.
P2860
Q27002386-B1149073-EFFF-4897-8CDF-1F3CF49B0B7EQ27022834-32B2EF73-B905-49F0-8ECE-98C1B127B691Q28072513-184A479A-F428-40A3-88C6-61F6CE22F784Q28084968-A0324F55-1DE6-4779-98E5-25F8B11B8785Q28283309-938333E8-149B-492A-A636-7E608AF8B6A6Q30656126-B54619CD-21B9-41A9-867E-0D0BC97269ACQ34411756-54E515D6-5E52-4579-A7A0-9F45CB1739DFQ34452426-0DF9031A-56DE-440C-AC57-759B10502439Q34714574-D7DF4612-8752-4031-8F71-BD0959EDA3BAQ34774884-9712DB02-8843-4761-8C46-4E90961B7E2EQ35157633-88771988-FD88-4404-91FA-1846281B0D18Q35168105-35717E43-88C0-45E8-9879-84312CCFC4B3Q35235832-68A566F5-0A28-4523-85AE-BA5A6BFB1D2AQ35238436-FDEFFA2F-3E09-47AA-BAE5-BB53AD8BAE92Q35593223-7330A91A-759F-480C-A068-12ACA8FDDBB4Q35606134-005E31B8-0A0B-4FE7-8A77-7307BDA650EAQ35624809-54E944BD-C499-428F-92DF-809CA24CA862Q35624814-7C1A35EB-23E5-4DA7-95EC-CCC5DB9BF88FQ35747298-484C38EE-0CFF-441F-8A13-8C1E23E2EA9EQ36061177-F697B300-D5FA-4D02-B3E5-B05EBC61B295Q36064912-8DA3BAEB-AA48-4012-B05C-F03E39D45B51Q36196676-411895DA-09EF-49C0-B4B6-E522A58CAC9AQ36293645-9B9A35A4-6CDF-4829-9FAF-D471ECA52FC0Q36355925-02BE95B9-0B49-49D1-8BBB-89503887C69AQ36782465-A6FC7510-B823-46DA-AEF3-664C816C04F3Q36797398-8E4BB027-03A2-465B-ACC5-39B698360B81Q37205832-0E3DE88D-4298-40F4-9623-903D74FA214CQ37554942-C6A56012-84CF-4BF1-808C-78769AC4C117Q37618855-F4589328-C449-474B-8F30-FDCEDD33FA06Q37714313-05A19C0D-A98D-4D0B-AFA3-6BBA76C5DB1AQ37940203-7DC5A765-4A74-4B75-8A4A-ED55C7D12481Q39899490-3DAC7AB7-BEC9-4932-9D25-18A89A4CF1B6Q42704187-A377F635-5E40-40C9-8593-4B856DC32B90Q47304027-8F5AA9A4-4C87-4415-A3B0-8161F0C00F3CQ47427416-DBB07171-4384-446A-8E9A-31DE46F2230BQ47795804-34498B3C-9B85-4E39-B99E-8E9CEC0D6579Q48106837-D876F2C2-FBA8-4144-B812-99D9E59B6060Q48117495-46BFEC24-D4AB-4273-8F98-7BE5D49A84A5Q50187592-0657E11E-CD88-4495-85C7-114406E0E447Q55010019-E834B022-297C-42B7-8796-20ED5B8F19CB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of HER2-overexpressing breast cancer.
@en
Treatment of HER2-overexpressing breast cancer.
@nl
type
label
Treatment of HER2-overexpressing breast cancer.
@en
Treatment of HER2-overexpressing breast cancer.
@nl
prefLabel
Treatment of HER2-overexpressing breast cancer.
@en
Treatment of HER2-overexpressing breast cancer.
@nl
P2860
P356
P1433
P1476
Treatment of HER2-overexpressing breast cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDQ421
P478
21 Suppl 7
P577
2010-10-01T00:00:00Z